Teleflex Awarded Peripheral Access Agreement with Premier, Inc.

Rhea-AI Summary

Teleflex Incorporated (TFX) has been awarded the Peripheral Access purchasing agreement with Premier, Inc., effective December 1st, 2023. This agreement allows Premier members to take advantage of special pricing and terms for Teleflex’s Peripheral Access products, including Peripherally Inserted Central Catheters (PICCs), PICC navigation equipment, and Midlines. The company is committed to delivering vascular access products designed to benefit clinicians and patients, while protecting against vascular access-related complications. Through its Arrow™ Peripheral Access products, Teleflex has recently refreshed the portfolio to optimize patient outcomes, reduce catheter colonization of major central line-associated infections (CLABSI) causing pathogens, and streamline insertion procedures. The new agreement with Premier is a significant opportunity for Teleflex to continue supporting healthcare providers in their efforts to reduce vascular-related complications.

WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it was awarded the Peripheral Access purchasing agreement with Premier, Inc. Effective December 1st, 2023, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Teleflex’s Peripheral Access products. Premier has awarded Teleflex a national multi-source agreement for Peripherally Inserted Central Catheters (PICCs), PICC navigation equipment, and Midlines.

“Teleflex strives to deliver vascular access products that are designed to benefit both clinicians and patients, while helping to protect against vascular access related complications^1-7,” said Lisa Kudlacz, President and General Manager, Teleflex Vascular. “We are pleased to continue to support Premier members with these PICC, Midline and Navigation products. Arrow^™ PICCs and Midlines are available in a traditional design or with Arrowg+ard Blue Advance^™ Protection Technology that’s proven effective to reduce catheter colonization by the major central line associated blood stream infection (CLABSI) causing pathogens.”^2-7

Teleflex, through its Arrow^™ Peripheral Access products, has recently refreshed the portfolio to help healthcare providers optimize patient outcomes, reduce catheter colonization of the major central line-associated infections (CLABSI) causing pathogens, and efficiently streamline insertion procedures^1-7.

The group purchasing agreement includes access to the:

• Arrow^™ VPS Rhythm DLX^™ Device capital equipment portfolio for PICC placements
• Arrow^™ PICCs preloaded with the NaviCurve^™ Stylet
• Arrow^™ VPS G4^™ Capital Equipment portfolio for PICC placements
• Traditional Arrow^™ PICCs
• Arrowg+ard Blue Advance^™ Antimicrobial/Antithrombogenic PICCs
• Traditional Arrow^™ Midlines
• Arrowg+ard Blue Advance^™ Antimicrobial/Antithrombogenic Midlines
• Arrow^™ Twin Cath^™ Peripheral Catheters
• Peripheral Access accessories
  

Teleflex is committed to supporting vascular access specialists in their efforts to reduce vascular-related complications by offering the world's first antimicrobial and antithrombogenic PICCs and Midlines.^3,7

Utilizing Arrowg+ard Blue Advance^™ PICCs and Midlines guards against CLABSI-causing pathogens in areas that are clinically out of reach.^3,7 This protection lasts while the line is in the patient for at least 30 days.^3,7

The next-generation VPS Rhythm^™ DLX Device provides real-time catheter tip location information by using the patient’s cardiac electrical activity. The device is also available with an optional integrated ultrasound featuring a Catheter-to-Vessel ratio tool that promotes standardization in vessel measurement. This device works in concert with the Arrow^™ PICC preloaded with the NaviCurve^™ Stylet, providing innovative tip navigation/location technologies.

The VPS Rhythm^™ DLX Device with TipTracker^™ Technology eliminates the need for a confirmatory x-ray⁸, helping the clinician insert seamlessly through ultrasound vessel assessment, PICC navigation, to final tip confirmation in the lower third of the superior vena cava.¹

Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,350 U.S. hospitals and 300,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost.

About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow^™, Deknatel^™, LMA^™, Pilling^™, QuikClot^™, Rüsch^™, UroLift^™ and Weck^™ – trusted brands united by a common sense of purpose.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

References
1. D041679 Benchtop Stylet Advancement in a Simulated Use Anatomical Model of NaviCurve™. Product Stylet/PICC Assemblies. Bench testing may not be indicative of clinical performance.
2. In-vitro data on file 2010: AVER-004371 and AVER-004483. No correlation between in-vitro/in-vivo testing methods and clinical outcomes have currently been ascertained.
3. As compared to uncoated PICCs, intravascular ovine model inoculated with Staph aureus: AVAR-000427. No correlation between in-vitro/in-vivo testing methods and clinical outcomes have currently been ascertained.
4. Grau D, Clarivet B, Lotthé A, Bommart S, Parer S. Complications with peripherally inserted central catheters (PICCs) used in hospitalized patients and outpatients: a prospective cohort study. Antimicrob Resist Infect Control. 2017;6:18. doi:10.1186/s13756-016-0161-0
5. Moreau N. Preventing PICC complications: whose line is it? Patient Safety Network. December 1, 2012. Accessed January 9, 2023. https://psnet.ahrq.gov/web-mm/preventing-picc-complications-whose-line-it
6. Estimating the additional hospital inpatient cost and mortality associated with selected hospital-acquired conditions. Agency for Healthcare Research and Quality. November 2017. Accessed November 9, 2022. https://www.ahrq.gov/hai/pfp/haccost2017-results.html
7. In-vitro data on file 2010: AVER-004371, AVER-004483 and AVAR-000427. No correlation between in vitro/in vivo testing methods and clinical outcomes has currently been ascertained.
8. DLX-200-OPM-US: VPS Rhythm™ DLX Operator's Manual.

Rx only

Contraindication:

Clinical assessment of the patient must be completed to ensure no contraindications exist. The Arrowg+ard Blue Advance™ PICC is contraindicated in the following areas:

• Patients with known hypersensitivity to chlorhexidine
• In presence of device related infections
• In presence of previous or current thrombosis in the intended vessel or along the catheterized vessel pathway.

No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.

For complete indications, contraindications, warnings, precautions, and adverse reactions, please refer to each referenced product's full package insert.

Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue Advance, Deknatel, LMA, NaviCurve, Pilling, QuikClot, Rüsch, TipTracker, UroLift, VPS Rhythm, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other trademarks are trademarks or registered trademarks of their respective owners.

© 2023 Teleflex Incorporated. All rights reserved. MC-009285

Contact:
Teleflex Incorporated:
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
investors.teleflex.com
610-948-2836

FAQ

What agreement has Teleflex Incorporated (TFX) been awarded?

Teleflex has been awarded the Peripheral Access purchasing agreement with Premier, Inc., effective December 1st, 2023.

What products are included in the agreement with Premier, Inc. for Teleflex?

The agreement includes special pricing and terms for Teleflex’s Peripheral Access products, including Peripherally Inserted Central Catheters (PICCs), PICC navigation equipment, and Midlines.

What is the goal of Teleflex in delivering vascular access products?

Teleflex is committed to delivering vascular access products designed to benefit both clinicians and patients, while helping to protect against vascular access-related complications.

What has Teleflex recently done to optimize patient outcomes?

Teleflex has recently refreshed its Arrow™ Peripheral Access products portfolio to optimize patient outcomes, reduce catheter colonization of major central line-associated infections (CLABSI) causing pathogens, and streamline insertion procedures.

Who is Premier, Inc. and what does it do?

Premier, Inc. is a leading healthcare improvement company, uniting an alliance of approximately 4,350 U.S. hospitals and 300,000 other providers to transform healthcare.